Mark Ballif, MD
Ophthalmology · Ogden, UTNPI 1376522573
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Rxsight Inc at 55.4% of the total. Reporting peaked in 2022 at $3,313 and has fallen 88.0% since, to $398 in 2024.
Across 72 payments — averaging $79.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$3K
- Johnson & Johnson Surgical Vision, Inc.$923
- Alcon$504
- AbbVie$332
- Glaukos Corporation$168
- Novartis$138
- plus $474 from 13 others
Across 58 payments — averaging $8280.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson Surgical Vision, Inc.$452K
- Rxsight Inc$28K
What the payments were for
- Consulting fees$3,00053%
- Speaking & faculty fees$260%
- Travel & lodging$67012%
- Food & beverage$1,96234%
- Gifts$391%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 7 | $3,157 |
| Johnson & Johnson Surgical Vision, Inc. | 11 | $923 |
| Alcon | 7 | $504 |
| AbbVie(2 entities) | 12 | $332 |
| Glaukos Corporation | 7 | $168 |
| Novartis | 9 | $138 |
| Bausch & Lomb Americas Inc. | 3 | $132 |
| Sun Pharmaceutical Industries Inc. | 1 | $102 |
| Dompe US, Inc. | 3 | $43 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Eyepoint US, Inc. | 2 | $27 |
| Shire North American Group Inc | 1 | $22 |
| Oyster Point Pharma, Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Kala Pharmaceuticals, Inc. | 1 | $19 |
| Alimera Sciences, Inc. | 1 | $16 |
| Sight Sciences, Inc. | 1 | $12 |
| Amgen | 1 | $12 |
| Genentech, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,696 in reported general payments places this provider in the 85th percentile of 191 ophthalmology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 20 | $666 |
| Ofloxacin | 32 | $352 |
| Latanoprost | 18 | $224 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Ogden
- Isha GuptaOgden$11K
- Michael WilcoxOgden$6K
- Jason RuppOgden$4K
- Brock HansenOgden$4K
- Claron AlldredgeOgden$3K
- Iqbal AhmedSalt Lake City$895K
- Robert CionniSalt Lake City$161K
- Ron LordSt. George$61K
- Zachary ZavodniSalt Lake City$51K
- Majid MoshirfarSalt Lake City$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.